31 research outputs found
17α-Ethynyl-5α-androstane-3α, 17β-diol Treatment of MNU-Induced Mammary Cancer in Rats
N-methyl-N-nitrosourea (MNU) induces estrogen-dependent mammary tumors in female
Lewis rats. We explored the antineoplastic activity of a synthetic androstane derivative,
17α-ethynyl-5α-androstane-3α, 17β-diol (HE3235), as a single agent or in combination
with docetaxel compared to tamoxifen, anastrazole, and docetaxel monotherapies against
MNU-induced mammary tumors in female Lewis rats. Treatment with HE3235 alone
rapidly reduced tumor burden, similar in effect to tamoxifen and anastrozole. The
combination of HE3235 with docetaxel was more effective than any single agent, although
without apparent toxicity. Only HE3235 or HE3235 plus docetaxel continued to suppress
tumor growth after cessation of treatment. HE3235 treatment increased
immunohistochemical markers of apoptosis and expression of proapoptotic genes and
estrogen receptor beta and decreased expression of antiapoptotic genes, androgen
receptor, and estrogen receptor alpha. These data warrant clinical investigation of HE3235
for breast cancer treatment
Molecular Targets for 17α-Ethynyl-5-Androstene-3β,7β,17β-Triol, an Anti-Inflammatory Agent Derived from the Human Metabolome
HE3286, 17α-ethynyl-5-androstene-3β, 7β, 17β-triol, is a novel synthetic compound related to the endogenous sterol 5-androstene-3β, 7β, 17β-triol (β-AET), a metabolite of the abundant adrenal steroid dehydroepiandrosterone (DHEA). HE3286 has shown efficacy in clinical studies in impaired glucose tolerance and type 2 diabetes, and in vivo models of types 1 and 2 diabetes, autoimmunity, and inflammation. Proteomic analysis of solid-phase HE3286-bound bead affinity experiments, using extracts from RAW 264.7 mouse macrophage cells, identified 26 binding partners. Network analysis revealed associations of these HE3286 target proteins with nodes in the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for type 2 diabetes, insulin, adipokine, and adipocyte signaling. Binding partners included low density lipoprotein receptor-related protein (Lrp1), an endocytic receptor; mitogen activated protein kinases 1 and 3 (Mapk1, Mapk3), protein kinases involved in inflammation signaling pathways; ribosomal protein S6 kinase alpha-3 (Rsp6ka3), an intracellular regulatory protein; sirtuin-2 (Sirt2); and 17β-hydroxysteroid dehydrogenase 1 (Hsd17β4), a sterol metabolizing enzyme
Kinetics of the dissociation of indium-(para-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogs from the monoclonal anti-hapten antibody CHA255
HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial.
Stability, characterization, and kinetics of 111in-labeled monoclonal antitumor antibodies in normal animals and nude mouse-human tumor models.
A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats
Tissue macrophage inflammatory pathways contribute to obesity-associated insulin resistance. Here, we have examined the efficacy and mechanisms of action of a novel anti-inflammatory compound (HE3286) in vitro and in vivo. In primary murine macrophages, HE3286 attenuates LPS- and TNFα-stimulated inflammation. In Zucker diabetic fatty rats, inflammatory cytokine/chemokine expression was downregulated in liver and adipose tissue by HE3286 treatment, as was macrophage infiltration into adipose tissue. In line with reduced inflammation, HE3286 treatment normalized fasting and fed glucose levels, improved glucose tolerance, and enhanced skeletal muscle and liver insulin sensitivity, as assessed by hyperinsulinemic euglycemic clamp studies. In phase 2 clinical trials, HE3286 treatment led to an enhancement in insulin sensitivity in humans. Gluconeogenic capacity was also reduced by HE3286 treatment, as evidenced by a reduced glycemic response during pyruvate tolerance tests and decreased basal hepatic glucose production (HGP) rates. Since serum levels of gluconeogenic substrates were decreased by HE3286, it indicates that the reduction of both intrinsic gluconeogenic capacity and substrate availability contributes to the decrease in HGP. Lipidomic analysis revealed that HE3286 treatment reduced liver cholesterol and triglyceride content, leading to a feedback elevation of LDL receptor and HMG-CoA reductase expression. Accordingly, HE3286 treatment markedly decreased total serum cholesterol. In conclusion, HE3286 is a novel anti-inflammatory compound, which displays both glucose-lowering and cholesterol-lowering effects